Edwards Lifesciences (EW) Stock
Heart valve and critical care monitoring leader. Here's the price, business snapshot, and what's worth knowing about Edwards Lifesciences in August 2026.
Edwards Lifesciences Corporation (EW) is a medical-technology company focused on heart valves and critical-care monitoring. It is best known for the Sapien transcatheter aortic valve replacement (TAVR) system and a broad range of surgical valves and haemodynamic monitoring products. Investors typically monitor Edwards for its leadership in structural heart therapies, clinical-driven innovation, and exposure to an ageing population that boosts demand for valve procedures. Revenue growth is linked to procedure volumes, reimbursement environments and the success of clinical trials and new indications. The company invests in R&D and selective acquisitions to extend its portfolio and geographic reach. Key risks include competition, regulatory and reimbursement shifts, and sensitivity to elective-procedure cycles. This is general educational information only and not personalised financial advice; values can rise or fall and past performance is not a reliable guide. Consider your own circumstances or consult a financial adviser before making investment decisions.
Why It’s Moving
EW is getting support from upbeat analyst sentiment and steady post-earnings buying
- Institutional buying has been the clearest near-term support, with large asset managers adding to or initiating positions in Edwards Lifesciences, reinforcing confidence in the company’s long-term heart-device franchise.
- Analyst sentiment has stayed constructive, with consensus still leaning toward a moderate buy and average targets sitting above the recent share price, suggesting Wall Street still sees room for execution to matter.
- Recent price action has also been shaped by the company’s stronger-than-expected second-quarter results, which showed demand and profitability holding up better than investors had feared.
EW is getting support from upbeat analyst sentiment and steady post-earnings buying
- Institutional buying has been the clearest near-term support, with large asset managers adding to or initiating positions in Edwards Lifesciences, reinforcing confidence in the company’s long-term heart-device franchise.
- Analyst sentiment has stayed constructive, with consensus still leaning toward a moderate buy and average targets sitting above the recent share price, suggesting Wall Street still sees room for execution to matter.
- Recent price action has also been shaped by the company’s stronger-than-expected second-quarter results, which showed demand and profitability holding up better than investors had feared.
Sixth Month Growth Performance
next-earnings-question
The next earnings date for EW is October 29, 2026. It is expected to cover Q3 2026 results. For investor planning, that timing is consistent with the company’s typical late-October reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Edwards Lifesciences stock with a target price of $95.77, indicating potential growth.
Financial Health
Edwards Lifesciences is performing well with strong profits and cash flow, supporting its growth potential.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Leader in TAVR
Edwards holds a strong position in transcatheter aortic valve replacement; adoption and expanded indications can support growth, though procedure volumes can fluctuate.
Clinical-driven innovation
Ongoing trials and new device launches are central to long-term prospects, but regulatory outcomes and trial timing can influence performance.
Demographics & reach
An ageing global population and geographic expansion present opportunities, while reimbursement and local regulation remain important considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
